How long do I have to stop SSRIs before ibogaine ceremony?

It depends on which SSRI. Fluoxetine (Prozac) requires 4–6 weeks of clearance after the final dose, due to its unusually long half-life and the active metabolite norfluoxetine. Most other SSRIs — sertraline, escitalopram, citalopram — require approximately 1–2 weeks from the final dose under physician supervision. These timelines are pharmacokinetic: the medication clears on its own schedule. A physician-supervised taper precedes the clearance period, adding additional time. A realistic minimum from beginning the taper to confirmed clearance for fluoxetine is 6–10 weeks.

Can I just reduce my SSRI dose instead of stopping completely?

No. Dose reduction is part of the supervised taper — it is not a substitute for full clearance. The contraindication for ibogaine requires the medication to be eliminated to below clinically relevant concentrations, not merely reduced. Taking a lower dose in the final weeks extends the clearance timeline rather than shortening it. The clearance clock begins at the final dose, regardless of what preceded it.

What happens if I take ibogaine while still on an SSRI?

Serotonin syndrome — a potentially life-threatening condition characterized by fever, muscle rigidity, agitation, and autonomic instability. Both SSRIs and ibogaine bind to the serotonin transporter; combining them creates the conditions for excess serotonergic activity. This is a documented pharmacological interaction. Providers who offer ibogaine to people currently on SSRIs without completed clearance are not operating safely. Inadequate medication screening is consistently associated with the most serious adverse events in ibogaine settings.

My doctor doesn't know about ibogaine — can they still help me taper?

Yes. Your physician does not need to know about or endorse ibogaine to help you taper safely from your SSRI. The taper itself is a standard medical process — gradual dose reduction with monitoring for discontinuation syndrome and confirmation of clearance. In Canada, ibogaine is not listed under the Controlled Drugs and Substances Act, so the conversation carries less legal complexity than in the United States. You can describe the need as a taper required before a procedure that needs serotonin clearance, without elaborating further if you prefer.

What if I cannot safely stop my SSRI — does that permanently disqualify me?

Not necessarily. It means the taper carries a clinical risk that has to be addressed before ibogaine ceremony is appropriate. Some people are on SSRIs for conditions where rapid discontinuation — even supervised — carries meaningful psychiatric risk. That clinical picture needs to be stabilized before a supervised taper is undertaken. The intake conversation at Transcend addresses your specific situation. A 'not now' is not the same as a permanent disqualification.

How is clearance confirmed before ibogaine ceremony?

Clearance is confirmed by your physician based on the medication's pharmacokinetic elimination timeline and your clinical state — not by how you feel. Standard markers include time from final dose (4–6 weeks for fluoxetine, 1–2 weeks for shorter-acting SSRIs), absence of serotonergic medication effects, and no concurrent use of other serotonergic agents. The medication review during intake at Transcend addresses clearance status as part of the pre-ceremony assessment. This is not something you assess yourself and report.

How Long Before Ibogaine Do You Have to Stop SSRIs?

Q: What is the SNRI clearance timeline compared to SSRIs?

SNRIs — venlafaxine, duloxetine — carry the same absolute contraindication. The clearance timelines are generally similar to shorter-acting SSRIs: approximately one week from the final dose under medical supervision. Venlafaxine is associated with particularly significant discontinuation syndrome and requires careful supervised tapering. The distinction from SSRIs is in the specific taper protocol, not the requirement for full clearance before ceremony.

Q: Does St. John's Wort count as a contraindication for ibogaine?

Yes. St. John's Wort has weak monoamine oxidase inhibitor (MAOI) activity and is an absolute contraindication for ibogaine ceremony. Stop it at least 2 weeks before ceremony. If you are taking it alongside an SSRI, disclose both to your physician — the combination adds serotonergic risk during the taper period. The fact that it is a plant-based supplement does not change its pharmacological activity.

SSRIs and SNRIs are absolute contraindications for ibogaine—not a caution, not something managed on a case-by-case basis, not a preference. The medication must be fully cleared from your system before any ceremony date can be scheduled. How long that takes depends on which SSRI you are taking: fluoxetine (Prozac) requires 4–6 weeks of clearance after the final dose. Most other SSRIs require approximately 1–2 weeks under physician supervision.

The timeline is not negotiable, and it cannot be compressed by taking lower doses in the final weeks. The clearance period is pharmacokinetic—the medication metabolizes out of the body on its own timeline, regardless of how ready you feel.

Key facts

Fluoxetine (Prozac): 4–6 weeks clearance after the final dose
Other SSRIs (sertraline, escitalopram, citalopram): ~1–2 weeks under physician supervision
SNRIs (venlafaxine, duloxetine): ~1 week, supervised
MAOIs: 2-week washout—absolute contraindication
St. John's Wort: stop 2 weeks before (weak MAOI activity)
The clearance clock starts at the final dose, not the start of taper

Why SSRIs are an absolute contraindication—not a caution

SSRIs and SNRIs elevate serotonin levels in the synaptic cleft by blocking the reuptake transporter. Ibogaine also has significant serotonergic activity—it binds to the serotonin transporter and produces serotonin release. Combining the two creates conditions for serotonin syndrome: a potentially life-threatening condition characterized by fever, agitation, muscle rigidity, and autonomic instability.

SSRIs and SNRIs are absolute contraindications—not preferences. The risk of serotonin syndrome from concurrent use is real and potentially fatal. No case is an exception to this rule. Providers who describe SSRIs as something to “be mindful of” or to “discuss” are not describing safe practice. The interaction is a documented pharmacological fact.

The 2023 Stanford study published in Nature Medicine that documented 88% reductions in PTSD symptoms and 87% reductions in depression symptoms at one month was conducted in a population screened specifically for this: no participant was on concurrent SSRIs or SNRIs. The outcomes that make ibogaine compelling were produced in people who had completed the clearance requirement. Ibogaine without that clearance does not produce those outcomes. It produces risk.

Fluoxetine (Prozac): the 4–6 week clearance requirement

Fluoxetine is a pharmacological outlier among SSRIs. Its half-life is 1–4 days for the parent compound and 4–16 days for its active metabolite, norfluoxetine. After the final dose, fluoxetine and norfluoxetine continue circulating at clinically relevant concentrations for weeks. The accepted clearance period before any procedure requiring serotonin-free conditions is 4–6 weeks from the last dose.

This is not a conservative estimate. It reflects the actual pharmacokinetic elimination timeline for a long-acting compound. Taking a lower dose of fluoxetine in the final weeks does not accelerate clearance—it extends the timeline, because the metabolite clears on its own schedule regardless of the preceding dose. The taper is still necessary to avoid discontinuation syndrome, but the clearance clock does not start until the final dose.

For someone currently on fluoxetine who wants to be evaluated for ibogaine ceremony: the 4–6 week clearance period is in addition to the taper. A realistic minimum from start of taper to confirmed clearance and ceremony readiness is 6–10 weeks—assuming no complications, no scheduling delays, and medical tests completed during the clearance window. Count from the date of your final dose, not the start of your taper.

Other SSRIs: the 1–2 week supervised taper

Sertraline, escitalopram, citalopram, and most other SSRIs have substantially shorter half-lives than fluoxetine. Under physician supervision, the clearance period for these medications is typically 1–2 weeks from the final dose.

“Clearance” refers to pharmacokinetic elimination, not to how you feel. Someone who stopped sertraline five days ago and feels fine has not necessarily cleared the medication to below clinically relevant concentrations. The physician conducting the taper confirms clearance—this is not something you assess yourself.

Paroxetine (Paxil) deserves specific mention. Its half-life is relatively short, but paroxetine is particularly associated with SSRI discontinuation syndrome—sudden discontinuation can produce significant withdrawal effects including dizziness, electric-shock sensations, and rebound anxiety. The taper for paroxetine typically requires more gradual dose reduction than other SSRIs, which extends the total timeline. This is an argument for planning ahead, not for delaying the conversation.

SNRIs and other serotonergic medications

Venlafaxine, duloxetine, and other serotonin-norepinephrine reuptake inhibitors carry the same absolute contraindication as SSRIs. The mechanism that creates serotonin syndrome risk overlaps directly. Clearance timelines for SNRIs are generally similar to shorter-acting SSRIs—approximately one week from the final dose under medical supervision. Venlafaxine is associated with particularly significant discontinuation syndrome; the supervised taper requires careful management.

St. John's Wort is a plant-based supplement with weak monoamine oxidase inhibitor (MAOI) activity. It is not an SSRI, but it creates serotonergic effects and is an absolute contraindication. Stop it at least 2 weeks before ceremony. If you are taking it alongside an SSRI, disclose both to your physician—the combination adds serotonergic risk during the taper period.

MAOIs—phenelzine, tranylcypromine—are absolute contraindications with a required washout of at least 2 weeks. The interaction between MAOIs and ibogaine's serotonergic activity is specifically documented. See the complete safety overview for ibogaine for the full contraindication picture.

What a physician-supervised taper actually involves

A physician-supervised taper means working with a doctor who knows what you are preparing for and monitors the process from the first dose reduction to confirmed clearance. It is not a conversation where you mention you are stopping your medication. It is an active medical process.

The physician reduces the dose gradually over a schedule designed to prevent discontinuation syndrome—the collection of symptoms that occur when serotonergic medications are stopped too quickly. The specific schedule depends on your current dose, how long you have been on the medication, and your history with previous discontinuation attempts.

After the final dose, the physician confirms clearance based on the medication's pharmacokinetic profile and your clinical state before any ceremony date is confirmed. In Canada, ibogaine is not listed under the Controlled Drugs and Substances Act, which means the conversation with your physician carries less legal complexity than the same conversation in the United States. Your doctor does not need to endorse ibogaine to help you taper safely from your SSRI. What to tell your doctor before ibogaine covers how to approach that conversation.

What not to do: self-tapering and common shortcuts

Stopping cold turkey to accelerate the process produces discontinuation syndrome without medical support to manage it. It does not shorten the pharmacokinetic clearance period—the medication clears on its own timeline regardless of how it was stopped. Stopping abruptly adds risk and discomfort without any benefit to the ceremony timeline.

Taking a very low dose for the final week and declaring yourself ready is not pharmacological clearance. Residual serotonergic activity does not disappear at a particular dose threshold—it follows the elimination timeline of the compound, not the dose you took last.

Adding alcohol, recreational drugs, or significant nutritional depletion during the taper period complicates the process and extends the time before you are genuinely ready. The complete preparation protocol covers the full pre-ceremony period and what it requires.

Who Is Not Right for This

Not everyone who is currently on an SSRI will be an appropriate candidate after taper. Some people are on SSRIs for conditions that make supervised discontinuation genuinely risky: severe recurrent major depression with high relapse vulnerability, panic disorder with a history of psychiatric emergency during previous discontinuation attempts, or conditions requiring continuous serotonergic support for baseline functioning.

If discontinuing your SSRI under physician supervision carries meaningful psychiatric risk—documented decompensation during previous tapers, active suicidality in the absence of medication—ibogaine ceremony is not the appropriate intervention at this time. This is an assessment of the taper itself, not a permanent verdict on candidacy.

Some of the harder conversations in the intake process happen with people who are currently on SSRIs and have found ibogaine as a potential solution to conditions those medications have not resolved. They have not arrived casually. They have arrived having done the research and carrying a specific hope. Being told directly that the taper they would need is clinically risky—or that other absolute contraindications rule out the pathway entirely regardless of medication status—is not what they came to hear. Saying it clearly, without softening, is the only honest response. A “not now” from screening is not a verdict that help is impossible. It is an accurate answer to whether this specific pathway is safe right now.

Ibogaine screening also disqualifies people independently of medication status: QT prolongation on a baseline EKG, severe liver or kidney disease, active psychosis, lithium use, and pregnancy are absolute contraindications that no taper resolves. The medication review is one part of a complete pre-ceremony medical assessment that addresses the full clinical picture.

Is This Right for You?

If you are currently on an SSRI or SNRI and are considering ibogaine ceremony, the first step is speaking with your prescribing physician about a supervised taper. That conversation happens before an application is submitted.

Once the taper is completed and clearance is confirmed, the intake process at Transcend reviews the taper timeline and your current clinical state as part of candidacy assessment. Clearance is necessary but not sufficient—candidacy also depends on the complete medical screening, including EKG and blood panel.

If you are on fluoxetine today, a realistic ceremony date is a minimum of 8–12 weeks away. Plan accordingly. The medicine will still be available when you are ready.

Submit an application. Review the full medical requirements at the FAQ. Read more about the screening process. Every application receives a personal response within 2–3 business days.